

11 March 2024

Lung Cancer Treatments

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) <5**
- **Amivantamab <5**
- **Atezolizumab Monotherapy <5 (lung)**
- **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel <5**
- **Dabrafenib + Trametinib <5**
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin Docetaxel Monotherapy <5**
- **Durvalumab <5**
- **Gemcitabine + Carboplatin <5**
- **Nitedanib + Docetaxel <5**
- **Nivolumab <5**
- **Osimertinib <5**
- **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5**
- **Paclitaxel <5**
- **Pembrolizumab Monotherapy 13**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) <5**
- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) <5**
- **Pemetrexed + Platinum (Carboplatin/Cisplatin) <5**
- **RET Inhibitors (Pralsetinib, Selpercatinib) <5**
- **Sotorasib <5**
- **Tepotinib <5**

11 March 2024

- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin** 5
- **Other active systemic anti-cancer therapy**
Nitedanib monotherapy <5 and Paclitaxel + Carboplatin 13
- **Palliative care only** Not available on RISOH (Regional Information System for Oncology and Haematology)

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:

- **Atezolizumab monotherapy**
- **Durvalumab**
- **Gemcitabine**
- **Nivolumab**
- **Osimertinib**
- **Pembrolizumab (Keytruda) Mono**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)**
- **Paclitaxel**
- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin**
- **Other active systemic anti-cancer therapy (SACT)**
- **Palliative care only**

This information is not available on RISOH (Regional Information System for Oncology and Haematology)